Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are
endogenous inhibitors of nitric oxide (NO) synthesis, and play a critical role in the process of …

We investigated the levels of asymmetric dimethylarginine (ADMA), an important
endogenous inhibitor of nitric oxide (NO), as related to metabolic risk factors known to …

Background Asymmetric NG, NG-dimethylarginine (ADMA) is an endogenous inhibitor of
endothelial nitric oxide (NO) synthase and its plasma concentration is elevated in patients …

Obstructive sleep apnea (OSA) occurs in 2% of middle‐aged women and 4% of middle‐
aged men and is considered an independent risk factor for cerebrovascular and …

The metabolic syndrome (MS) is a cluster of pathophysiological alterations that includes the
presence of hypertension, insulin resistance, dyslipidemia, and abdominal obesity. MS is …

In our manuscript “Prospective epidemiologic evidence of a 'protective'effect of smoking on
metabolic syndrome and diabetes among Turkish women—without associated overall …

Background: Endothelium-derived nitric oxide plays a crucial role in the regulation of
vascular tone and the development of cardiovascular disease. The endogenous nitric oxide …

Methods The study participants consisted of 78 normotensive type 2 diabetics. The SQ of all
participants was assessed using the Pittsburgh Sleep Quality Index (PSQI). Patients with a …

Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of
endothelium nitric oxide synthase (NOS). ADMA binds to a substrate-binding site of NOS …

Background: It has been reported that estrogen deficiency after menopause might cause a
decrement in nitric oxide (NO) bioavailability by increasing the level of asymmetric …